Abgenix Run-Up In Value Ends Cell Genesys/Genzyme Merger
Executive Summary
Cell Genesys spin-off Abgenix' success in marketing its XenoMouse technology has helped terminate a proposed merger between Genzyme and Cell Genesys.
You may also be interested in...
The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.
Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.
The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.
Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.
Amgen Is Biotech Again; Genomic Data Drives Sector To New Highs
Amgen is reclaiming its biotech identity as Wall Street rushes back to biotechnology.